{"id":"NCT02563067","sponsor":"Novartis Pharmaceuticals","briefTitle":"Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.","officialTitle":"A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of QAW039 When Added to Existing Asthma Therapy in Patients With Uncontrolled Severe Asthma.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-12-03","primaryCompletion":"2019-07-04","completion":"2019-08-02","firstPosted":"2015-09-29","resultsPosted":"2021-05-03","lastUpdate":"2021-05-03"},"enrollment":877,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"DRUG","name":"QAW039","otherNames":[]},{"type":"DRUG","name":"QAW039","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"QAW039 150 mg","type":"EXPERIMENTAL"},{"label":"QAW039 450 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study aimed to determine the efficacy and safety of QAW039 and QAW039 450 mg compared to placebo, when added to GINA (Global Initiative for Asthma) steps 4 and 5 standard-of- care (SoC) asthma therapy (GINA 2016) in the following two populations:\n\n* patient with inadequately controlled severe asthma and high eosinophil counts (eosinophil count at Visit 1 ≥250 cells/ µl) (sub-population)\n* patients with inadequately controlled severe asthma (overall study population) Inadequate control is defined as partly controlled or uncontrolled asthma (GINA 2016)","primaryOutcome":{"measure":"Rate of Moderate-to-severe Asthma Exacerbations During the 52-week Treatment Period in High Eosinophils Subpopulation","timeFrame":"52 weeks","effectByArm":[{"arm":"QAW039 150 mg","deltaMin":0.73,"sd":null},{"arm":"QAW039 450 mg","deltaMin":0.76,"sd":null},{"arm":"Placebo","deltaMin":1.06,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"0.059"},{"comp":"OG001 vs OG002","p":"0.114"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":7},"locations":{"siteCount":163,"countries":["United States","Argentina","Canada","Czechia","Greece","India","Israel","Italy","Japan","Lebanon","Malaysia","Mexico","Netherlands","Russia","Serbia","Slovakia","South Africa","Spain","Taiwan"]},"refs":{"pmids":["32979986"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":20,"n":296},"commonTop":["Asthma","Nasopharyngitis","Bronchitis","Viral upper respiratory tract infection","Headache"]}}